GlaxoSmithKline (NYSE: GSK) reported Q1 EPS of GBP0.43, GBP0.48 worse than the analyst estimate of GBP0.91. Revenue for the quarter came in at GBP7.4 billion versus the consensus estimate of GBP8.85 billion.

2024 guidance updated and dividends:

GSK has upgraded its full-year 2024 guidance. The company now expects 2024 turnover growth towards the upper part of 5% to 7% range; Core operating profit growth of 9% to 11% (previously 7% to 10%); Core EPS growth of 8% to 10% (previously 6% to 9%).
Dividend declared of 15p for Q1 2024; 60p expected for Full Year 2024.

For earnings history and earnings-related data on GlaxoSmithKline (GSK) click here.